Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.700 USD | -0.51% |
|
-4.15% | +3.97% |
Feb. 10 | CVS Health Fiscal 2025 EPS Outlook Seen Lower on Health Care Benefits Segment, UBS Says | MT |
Feb. 07 | Walgreens Boots Alliance Cuts Stake in Cencora to About 6% | MT |
Fiscal Period: August | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 140B | 133B | 133B | 139B | 148B | |||||
Total Revenues | 140B | 133B | 133B | 139B | 148B | |||||
Cost of Goods Sold, Total | 112B | 104B | 104B | 112B | 121B | |||||
Gross Profit | 28.02B | 28.07B | 28.27B | 27.07B | 26.52B | |||||
Selling General & Admin Expenses, Total | 25.03B | 24.38B | 25.82B | 25.78B | 25.68B | |||||
Other Operating Expenses, Total | 25.03B | 24.38B | 25.82B | 25.78B | 25.68B | |||||
Operating Income | 2.99B | 3.69B | 2.45B | 1.29B | 839M | |||||
Interest Expense, Total | -584M | -502M | -420M | -606M | -584M | |||||
Interest And Investment Income | - | 11M | 24M | 26M | - | |||||
Net Interest Expenses | -584M | -491M | -396M | -580M | -584M | |||||
Income (Loss) On Equity Invest. | 382M | -512M | 468M | 285M | 230M | |||||
Currency Exchange Gains (Loss) | -52M | -83M | 523M | -273M | -39M | |||||
Other Non Operating Income (Expenses) | -69M | 83M | -603M | 275M | -877M | |||||
EBT, Excl. Unusual Items | 2.67B | 2.68B | 2.44B | 994M | -431M | |||||
Restructuring Charges | -267M | -24M | -190M | -1.18B | -891M | |||||
Merger & Related Restructuring Charges | - | - | -223M | -323M | -542M | |||||
Impairment of Goodwill | -1.7B | - | - | - | -12.7B | |||||
Gain (Loss) On Sale Of Investments | -70M | 290M | 2.94B | 1.96B | 1.25B | |||||
Gain (Loss) On Sale Of Assets | 308M | 367M | 619M | 925M | 293M | |||||
Asset Writedown | -155M | -207M | -783M | -299M | -721M | |||||
Legal Settlements | - | -75M | -768M | -7.47B | -561M | |||||
Other Unusual Items | - | -414M | -4M | - | 102M | |||||
EBT, Incl. Unusual Items | 784M | 2.62B | 4.04B | -5.39B | -14.2B | |||||
Income Tax Expense | 360M | 667M | -30M | -1.86B | 1.25B | |||||
Earnings From Continuing Operations | 424M | 1.96B | 4.06B | -3.53B | -15.45B | |||||
Earnings Of Discontinued Operations | - | 548M | - | - | - | |||||
Net Income to Company | 424M | 2.5B | 4.06B | -3.53B | -15.45B | |||||
Minority Interest | 32M | 39M | 272M | 448M | 6.81B | |||||
Net Income - (IS) | 456M | 2.54B | 4.34B | -3.08B | -8.64B | |||||
Net Income to Common Incl Extra Items | 456M | 2.54B | 4.34B | -3.08B | -8.64B | |||||
Net Income to Common Excl. Extra Items | 456M | 1.99B | 4.34B | -3.08B | -8.64B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.52 | 2.94 | 5.02 | -3.57 | -10.01 | |||||
Basic EPS - Continuing Operations | 0.52 | 2.31 | 5.02 | -3.57 | -10.01 | |||||
Basic Weighted Average Shares Outstanding | 879M | 865M | 864M | 863M | 863M | |||||
Net EPS - Diluted | 0.52 | 2.93 | 5.01 | -3.57 | -10.01 | |||||
Diluted EPS - Continuing Operations | 0.52 | 2.3 | 5.01 | -3.57 | -10.01 | |||||
Diluted Weighted Average Shares Outstanding | 880M | 866M | 866M | 863M | 863M | |||||
Normalized Basic EPS | 1.93 | 1.99 | 2.08 | 1.24 | 7.58 | |||||
Normalized Diluted EPS | 1.93 | 1.98 | 2.07 | 1.24 | 7.58 | |||||
Dividend Per Share | 1.84 | 1.88 | 1.91 | 1.92 | 1.23 | |||||
Payout Ratio | 383.11 | 63.61 | 38.25 | -53.86 | -14.59 | |||||
American Depositary Receipts Ratio (ADR) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |||||
Supplemental Items | ||||||||||
EBITDA | 4.6B | 5.38B | 4.13B | 3.17B | 2.88B | |||||
EBITA | 3.45B | 4.21B | 3.09B | 2.1B | 1.8B | |||||
EBIT | 2.99B | 3.69B | 2.45B | 1.29B | 839M | |||||
EBITDAR | 8.7B | 9.18B | 8.09B | 7.31B | 7.16B | |||||
Effective Tax Rate - (Ratio) | 45.92 | 25.44 | -0.74 | 34.5 | -8.77 | |||||
Current Domestic Taxes | 199M | 194M | 76M | 229M | 143M | |||||
Current Foreign Taxes | 204M | 234M | 260M | 283M | 185M | |||||
Total Current Taxes | 403M | 428M | 336M | 512M | 328M | |||||
Deferred Domestic Taxes | -81M | -56M | -98M | -2.25B | 1.17B | |||||
Deferred Foreign Taxes | 38M | 295M | -268M | -120M | -251M | |||||
Total Deferred Taxes | -43M | 239M | -366M | -2.37B | 918M | |||||
Normalized Net Income | 1.7B | 1.72B | 1.8B | 1.07B | 6.54B | |||||
Interest Capitalized | - | - | - | - | - | |||||
Interest on Long-Term Debt | 56M | 52M | 50M | 51M | 53M | |||||
Non-Cash Pension Expense | -142M | -194M | -131M | -76M | -8M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 534M | 772M | 862M | 775M | 694M | |||||
Selling and Marketing Expenses | 534M | 772M | 862M | 775M | 694M | |||||
Research And Development Expense From Footnotes | 314M | 284M | 307M | 371M | 414M | |||||
Net Rental Expense, Total | 4.09B | 3.8B | 3.96B | 4.14B | 4.27B | |||||
Imputed Operating Lease Interest Expense | 659M | 406M | 376M | 566M | 584M | |||||
Imputed Operating Lease Depreciation | 3.43B | 3.39B | 3.58B | 3.57B | 3.69B | |||||
Stock-Based Comp., SG&A Exp. (Total) | 137M | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | - | 155M | 391M | 385M | 182M | |||||
Total Stock-Based Compensation | 137M | 155M | 391M | 385M | 182M |